Rigel Pharmaceuticals to Present at UBS Warburg Conference on September 22
Thursday, September 18, 2003 07:31 AM ET Printer-friendly version
SOUTH SAN FRANCISCO, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL, news) today announced that Chief Executive Officer James M. Gower is scheduled to present at the UBS Warburg Global Life Sciences Conference at 11:30 a.m. Eastern Time, September 22, 2003 at The Plaza Hotel, New York.
Event: UBS Warburg Global Life Sciences Conference
Location: The Plaza Hotel
Fifth Avenue at Central Park South, New York, NY
Date: September 22, 2003
Speaker: James M. Gower, Chief Executive Officer,
Rigel Pharmaceuticals, Inc.
Monday, September 22, 2003,
11:30 a.m. - 12:00 p.m. Eastern Time
Highlights: Mr. Gower will discuss Rigel's current and upcoming
clinical candidates in allergic rhinitis, hepatitis C,
rheumatoid arthritis and asthma. He will discuss the
company's unique approach to functional genomics and
earlier research projects. Mr. Gower will also discuss
Rigel's recent financing.
For those who are unable to attend the conference, there will be a live audio webcast of Gower's presentation at the UBS website (http://www.ibb.ubs.com) and a replay available from the same site beginning September 23, 2003 at 11:30 a.m. Eastern Time through October 25, 2003.
About Rigel (http://www.rigel.com)
Rigel's mission is to become a source of novel, small-molecule drugs to meet large, unmet medical needs. Rigel has identified three lead product development programs: mast cell inhibition to treat immunologic diseases such as asthma/allergy and autoimmune disorders, antiviral agents to treat hepatitis C, and ligases, a new class of cancer drug targets. In addition to the clinical testing of R112 for allergic rhinitis, Rigel plans to begin clinical trials of three additional drug candidates, for the treatment of hepatitis C, rheumatoid arthritis and asthma by the end of 2004.
Source: Rigel Pharmaceuticals, Inc. |
